JP2023554097A5 - - Google Patents

Info

Publication number
JP2023554097A5
JP2023554097A5 JP2023537140A JP2023537140A JP2023554097A5 JP 2023554097 A5 JP2023554097 A5 JP 2023554097A5 JP 2023537140 A JP2023537140 A JP 2023537140A JP 2023537140 A JP2023537140 A JP 2023537140A JP 2023554097 A5 JP2023554097 A5 JP 2023554097A5
Authority
JP
Japan
Application number
JP2023537140A
Other languages
Japanese (ja)
Other versions
JP2023554097A (ja
JPWO2022129512A5 (https=
Filing date
Publication date
Priority claimed from PCT/EP2020/086600 external-priority patent/WO2021122866A1/en
Application filed filed Critical
Priority claimed from PCT/EP2021/086471 external-priority patent/WO2022129512A1/en
Publication of JP2023554097A publication Critical patent/JP2023554097A/ja
Publication of JP2023554097A5 publication Critical patent/JP2023554097A5/ja
Publication of JPWO2022129512A5 publication Critical patent/JPWO2022129512A5/ja
Pending legal-status Critical Current

Links

JP2023537140A 2020-12-17 2021-12-17 二機能性抗pd1/il-7分子 Pending JP2023554097A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/EP2020/086600 WO2021122866A1 (en) 2019-12-17 2020-12-17 Bifunctional molecules comprising an il-7 variant
EPPCT/EP2020/086600 2020-12-17
EP21305462.0 2021-04-09
EP21305462 2021-04-09
EP21200350 2021-09-30
EP21200350.3 2021-09-30
PCT/EP2021/086471 WO2022129512A1 (en) 2020-12-17 2021-12-17 Bifunctional anti-pd1/il-7 molecules

Publications (3)

Publication Number Publication Date
JP2023554097A JP2023554097A (ja) 2023-12-26
JP2023554097A5 true JP2023554097A5 (https=) 2024-12-25
JPWO2022129512A5 JPWO2022129512A5 (https=) 2024-12-25

Family

ID=79024880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537140A Pending JP2023554097A (ja) 2020-12-17 2021-12-17 二機能性抗pd1/il-7分子

Country Status (9)

Country Link
US (1) US20240067727A1 (https=)
EP (1) EP4263606A1 (https=)
JP (1) JP2023554097A (https=)
KR (1) KR20230129441A (https=)
AU (1) AU2021402065A1 (https=)
CA (1) CA3201729A1 (https=)
IL (1) IL303745A (https=)
MX (1) MX2023007301A (https=)
WO (1) WO2022129512A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023281479A1 (en) * 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023281485A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20240424127A1 (en) * 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
WO2026052654A1 (en) * 2024-09-03 2026-03-12 F. Hoffmann-La Roche Ag Cytokine receptor agonist

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
CA2551915C (en) * 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2902739C (en) 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
CN111491361B (zh) 2016-02-02 2023-10-24 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
KR102561356B1 (ko) 2016-09-14 2023-08-03 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
WO2019144945A1 (en) * 2018-01-25 2019-08-01 I-Mab Anti-pd-l1 antibody and il-7 fusions
SG11202010163QA (en) * 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US11505595B2 (en) * 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
CN112566801B (zh) 2018-07-10 2024-03-01 依维柯股份公司 用于车辆的悬架
EP4257199A3 (en) 2018-12-21 2024-01-10 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
CN113614109A (zh) * 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
CN110256583B (zh) * 2019-07-11 2022-05-20 中国科学院生物物理研究所 一种il-2突变体与抗体的融合蛋白及其应用
AU2020406083A1 (en) * 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2023554097A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)